Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 51.0% in June

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,452,613 shares, a decrease of 51.0% from the June 15th total of 2,962,839 shares. Based on an average daily trading volume, of 1,062,756 shares, the short-interest ratio is presently 1.4 days. Approximately 4.3% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP purchased a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent filing with the SEC. The firm purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics at the end of the most recent quarter. 6.17% of the stock is owned by institutional investors and hedge funds.

Theriva Biologics Trading Down 6.0%

NYSEAMERICAN:TOVX opened at $0.23 on Friday. The stock has a market capitalization of $7.71 million, a price-to-earnings ratio of -0.01 and a beta of 1.09. Theriva Biologics has a 1 year low of $0.16 and a 1 year high of $0.86. The stock has a fifty day moving average price of $0.27 and a two-hundred day moving average price of $0.24. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.63 and a current ratio of 1.63.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share for the quarter. The firm had revenue of $0.30 million for the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group raised Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $1.00.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.